CIK 0001178670
- Large accelerated filer
ALNYLAM PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- ALNY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 770602661
- Phone
- +1 617-551-8200
- Business address
- 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142
- Former names
- ALNYLAM PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $543,126
- in 2 filings
- Open-market sales, last 90 days
- $398,855
- in 1 filing
Net +$144,271. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-08-20 | Greenstreet Yvonne Chief Executive Officer | Exercise or conversion · Stock Option (right to buy) 10b5-1 | −15,000 | 2,352 | ||
| 2024-08-12 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Exercise or conversion 10b5-1 | +6,667 | $97.72 | $651K | 20,848 |
| 2024-08-12 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Exercise or conversion 10b5-1 | +14,058 | $85.00 | $1.2M | 34,906 |
| 2024-08-12 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −1,421 | $268.66 | $382K | 33,485 |
| 2024-08-12 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −9,662 | $270.17 | $2.6M | 23,823 |
| 2024-08-12 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −5,736 | $271.32 | $1.6M | 18,087 |
| 2024-08-12 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −3,913 | $272.43 | $1.1M | 14,174 |
| 2024-08-12 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −1,158 | $273.73 | $317K | 13,016 |
| 2024-08-12 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −135 | $274.65 | $37K | 12,881 |
| 2024-08-12 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Exercise or conversion · Stock Option (right to buy) 10b5-1 | −14,058 | 2,192 | ||
| 2024-08-12 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Exercise or conversion · Stock Option (right to buy) 10b5-1 | −6,667 | 0 | ||
| 2024-08-06 | Ausiello Dennis A Director | Exercise or conversion 10b5-1 | +11,250 | $131.21 | $1.5M | 11,386 |
| 2024-08-06 | Ausiello Dennis A Director | Exercise or conversion 10b5-1 | +9,000 | $105.26 | $947K | 20,386 |
| 2024-08-06 | Ausiello Dennis A Director | Sale 10b5-1 | −1,627 | $259.56 | $422K | 18,759 |
| 2024-08-06 | Ausiello Dennis A Director | Sale 10b5-1 | −3,742 | $260.40 | $974K | 15,017 |
| 2024-08-06 | Ausiello Dennis A Director | Sale 10b5-1 | −6,212 | $261.63 | $1.6M | 8,805 |
| 2024-08-06 | Ausiello Dennis A Director | Sale 10b5-1 | −4,367 | $262.79 | $1.1M | 4,438 |
| 2024-08-06 | Ausiello Dennis A Director | Sale 10b5-1 | −3,408 | $263.72 | $899K | 1,030 |
| 2024-08-06 | Ausiello Dennis A Director | Sale 10b5-1 | −632 | $264.95 | $167K | 398 |
| 2024-08-06 | Ausiello Dennis A Director | Sale 10b5-1 | −262 | $266.45 | $70K | 136 |
Page 42 of 80 · 1,590 trades